July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
The negative psychosocial impact of thyroid eye disease - comparing results from the CIRTED trial with strabismus and other facially disfiguring conditions.
Author Affiliations & Notes
  • Shokufeh Tavassoli
    Bristol Eye Hospital, Bristol, United Kingdom
  • Rathie Rajendram
    Moorfields Eye Hospital, London, United Kingdom
  • Victoria Wilson
    University of Bristol, Bristol, United Kingdom
  • Paul White
    University of West of England, Bristol, United Kingdom
  • Jimmy Uddin
    Moorfields Eye Hospital, London, United Kingdom
  • Colin Dayan
    University of Cardiff, Cardiff, United Kingdom
  • Richard W. J. Lee
    Bristol Eye Hospital, Bristol, United Kingdom
  • Sue Jackson
    University of West of England, Bristol, United Kingdom
  • Footnotes
    Commercial Relationships   Shokufeh Tavassoli, None; Rathie Rajendram, None; Victoria Wilson, None; Paul White, None; Jimmy Uddin, None; Colin Dayan, None; Richard Lee, None; Sue Jackson, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5618. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shokufeh Tavassoli, Rathie Rajendram, Victoria Wilson, Paul White, Jimmy Uddin, Colin Dayan, Richard W. J. Lee, Sue Jackson; The negative psychosocial impact of thyroid eye disease - comparing results from the CIRTED trial with strabismus and other facially disfiguring conditions.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5618.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Thyroid eye disease (TED) is an inflammatory orbital condition causing facial disfigurement and visual dysfunction. Previous reports have suggested this has an adverse impact on patients’ quality of life. The purpose of our study was to evaluate this in a UK cohort and to compare the psychosocial impact of TED to that of strabismus and other facially disfiguring conditions.

Methods : Participants enrolled in the Combined Immunosuppression and Radiotherapy in Thyroid Eye Disease (CIRTED) trial were given a questionnaire pack comprising scales measuring general anxiety and depression (HADS); quality of life (WHOQoL-Bref); and social anxiety and social avoidance as a result of appearance (DAS-24). The comparison groups were from previously reported data on patients with strabismus, as well as those with pre-treatment facial burns, head and neck cancer, and other maxillofacial conditions.

Results : 167 participants were enrolled in the CIRTED trial. Of these 142 (70.4% female, 29.6% male; age range: 23-73 years) completed pre-treatment questionnaires. Independent sample t-test analyses showed significantly greater levels of HADS depression (p<0.001; medium effect size, 0.7), HADS general anxiety (p<0.001; medium effect size, 0.7) and DAS-24 social anxiety (p<0.008; moderate effect size, 0.4) in the CIRTED group compared to the group with strabismus. Further more the CIRTED group showed significantly greater levels of HADS depression (p<0.001; p<0.027, medium effect size for both, 0.5), HADS general anxiety (p<0.004; p<0.003, medium effect size for both, 0.6) and DAS-24 social anxiety (p<0.001; medium effect size, 0.7; p<0.001, large effect size, 0.9) compared to both the maxillofacial conditions and facial burns groups, respectively. The CIRTED patients reported comparable levels of depression, general anxiety, social anxiety and reduced quality of life as the head and neck cancer patients.

Conclusions : The psychosocial impact of TED was significantly greater than that of strabismus, facial burns and other maxillofacial conditions, and equivalent to that of head and neck cancer.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×